GRI - GRI Bio, Inc.

1.51
0.070   4.636%

Share volume: 866,838
Last Updated: 04-04-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$1.44
0.07
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 17%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.58%
1 Month
-76.98%
3 Months
-81.59%
6 Months
-81.59%
1 Year
-81.59%
2 Year
-81.59%
Key data
Stock price
$1.51
P/E Ratio 
0.00
DAY RANGE
$1.21 - $1.70
EPS 
-$21.05
52 WEEK RANGE
$1.21 - $11.12
52 WEEK CHANGE
-$81.59
MARKET CAP 
7.400 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$2,738,484
AVERAGE 30 VOLUME 
$839,318
Company detail
CEO: W. Marc Hertz
Region: US
Website: gribio.com
Employees: 1
IPO year: 2008
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.

Recent news
loading